ASTIM ALLERJI IMMUNOLOJI, cilt.13, sa.3, ss.130-133, 2015 (ESCI)
Objective: L-asparaginase (L-ASP) is one of the indispensible medications used in the treatment of acute lymphoblastic leukemia (ALL); however, the allergic reactions caused by the drug limit its use. 52 patients (37 were low risk, 15 were high risk) who were followed for ALL between January 2010 and July 2014 and who developed local and systemic reactions associated with Escherichia coli L-ASP were evaluated.